|
ANNOUNCEMENT TO BE MADE BY
THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH RULE 2 OF
THE AIM RULES FOR COMPANIES ("AIM RULES")
|
|
|
|
COMPANY NAME:
|
|
Amur Minerals Corporation ("Amur" or
the "Company")
The Company is proposing to change
its name to CRISM Therapeutics Corporation upon completion of a
reverse takeover ("RTO") of Extruded Pharmaceuticals Limited ("EPL"
or "Extruded", and together with Amur, the "Enlarged
Group").
|
|
COMPANY REGISTERED OFFICE ADDRESS AND
IF DIFFERENT, COMPANY TRADING ADDRESS (INCLUDING
POSTCODES):
|
|
Amur
and the Enlarged Group, post Admission:
Kingston Chambers
PO Box 173
Road Town
Tortola
British Virgin Islands
Extruded:
Douglas Bank House
Wigan Lane
Wigan
WN1 2TB
|
|
COUNTRY OF INCORPORATION:
|
|
British Virgin Islands
|
|
COMPANY WEBSITE ADDRESS CONTAINING
ALL INFORMATION REQUIRED BY AIM RULE 26:
|
|
Currently:
www.amurminerals.com
From Admission:
www.crismtherapeutics.com
|
|
COMPANY BUSINESS (INCLUDING
MAIN COUNTRY OF OPERATION) OR, IN THE CASE
OF AN INVESTING COMPANY, DETAILS OF ITS
INVESTING POLICY). IF THE
ADMISSION IS SOUGHT AS A RESULT OF A
REVERSE TAKE-OVER UNDER RULE 14, THIS SHOULD BE STATED:
|
|
Amur is currently classified as an
AIM Rule 15 cash shell. It proposes to acquire 100 per cent. of EPL
by way of an RTO under AIM Rule 14. Amur has called a general
meeting of the Company in order to approve the proposed RTO,
approve a change of name to CRISM Therapeutics, and approve a share
consolidation of 1 new ordinary share for every 160 existing
ordinary shares.
EPL is a UK-based pharmaceutical
company which was founded in March 2016. EPL has developed an
innovative drug delivery technology to improve the clinical
performance of cancer treatments for solid tumours through the
local delivery of chemotherapy drugs.
ChemoSeed®, EPL's lead
product, can be implanted directly into the tumour or the resection
margin following the removal of a tumour. This ensures that
therapeutic concentrations of chemotherapy drugs reach the
deep-seated tumour tissue or cover the entire resection margin. In
the case of treating high grade glioma, ChemoSeeds can be implanted
during surgery thereby bypassing the blood brain barrier, which
prevents other treatments from being able to reach the tumour and
be effective.
ChemoSeed addresses a significant,
unmet medical need in the treatment of glioblastoma and high grade
glioma. There are no current cures and present treatments merely
seek to simply extend life, often by just a few months, with
serious adverse side effects.
Each ChemoSeed consist of a
chemotherapeutic agent (irinotecan) and a bioresorbable polymer,
both of which have been previously administered to the brain with
no toxicity issues. This, combined with the target markets for
ChemoSeed being unmet medical needs, means EPL could potentially
receive conditional marketing authorisation in the UK on the back
of positive Phase II clinical trial data. This authorisation could
be received as early as 2028, therefore reducing the time and cost
to commercialisation of irinotecan loaded ChemoSeeds for
glioblastoma and high-grade glioma treatment.
|
|
DETAILS OF SECURITIES TO BE ADMITTED
INCLUDING ANY RESTRICTIONS AS TO TRANSFER
OF THE SECURITIES (i.e. where known, number and type of shares,
nominal value and issue price to which it seeks admission and the
number and type to be held as treasury shares):
|
|
The Company currently has
1,392,872,315 Exiting Ordinary Shares in issue.
Assuming the proposed share
consolidation is approved, there would be 32,678,150 ordinary
shares of no par value.
No restrictions on
transferability.
|
|
CAPITAL TO BE RAISED ON ADMISSION
(AND/OR SECONDARY OFFERING) AND ANTICIPATED MARKET CAPITALISATION
ON ADMISSION:
|
|
No capital to be raised on
admission.
Anticipated market capitalisation on
admission: £7.5 million.
|
|
PERCENTAGE OF AIM SECURITIES
NOT IN PUBLIC HANDS AT
ADMISSION:
|
|
73.26 per cent.
|
|
DETAILS OF ANY OTHER EXCHANGE OR
TRADING PLATFORM TO WHICH THE AIM
SECURITIES (OR OTHER SECURITIES OF THE COMPANY) ARE OR WILL BE
ADMITTED OR TRADED:
|
|
Not applicable
|
|
THE COMPANY HAS APPLIED FOR THE
VOLUNTARY CARBON MARKET DESIGNATION
(Y/N)
|
|
No
|
|
FULL NAMES AND FUNCTIONS OF
DIRECTORS AND PROPOSED DIRECTORS
(underlining the first name by which each is known or including any
other name by which each is known):
|
|
Existing Directors, all to step
down at Admission:
Robert William Schafer, Non-Executive Chairman
Robin Jay
Young, Chief Executive
Officer
Thomas (Tom)
Edward Bowens, Non-Executive
Director
Paul Terence
Gazzard, Independent
Non-Executive Director
Proposed Directors, to join the
board from Admission:
Dr Nermeen
Yunus Varawalla, Independent
Non-Executive Chair
Andrew James
Webb, Chief Executive
Officer
Dr Christopher (Chris) McConville, Chief Scientific Officer
Gerald (Gerry) Douglas Beaney, Independent Non-Executive
Director
|
|
FULL NAMES AND HOLDINGS OF
SIGNIFICANT SHAREHOLDERS EXPRESSED AS A
PERCENTAGE OF THE ISSUED SHARE CAPITAL, BEFORE AND AFTER ADMISSION
(underlining the first name by which each is known or including any
other name by which each is known):
|
|
|
Name
|
Percentage of existing
ordinary share capital
|
Percentage of enlarged share
capital upon Admission
|
|
|
|
|
|
Andrew Webb
|
-
|
18.63%
|
|
Christopher (Chris) McConville
|
-
|
15.02%
|
|
Brian Murray
|
-
|
15.02%
|
|
David Lawton
|
-
|
15.02%
|
|
Linista Group Inc
|
-
|
4.52%
|
|
|
NAMES OF ALL PERSONS TO BE DISCLOSED
IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM
RULES:
|
|
Not applicable
|
|
(i)
ANTICIPATED ACCOUNTING REFERENCE DATE
(ii) DATE TO WHICH
THE MAIN FINANCIAL INFORMATION IN THE
ADMISSION DOCUMENT HAS BEEN PREPARED (this may be represented by
unaudited interim financial information)
(iii) DATES BY WHICH IT
MUST PUBLISH ITS FIRST THREE REPORTS PURSUANT TO AIM RULES 18 AND
19:
|
|
i) 31
December
ii) Amur: 31
December 2023; Extruded: 31 December 2023
iii) Interim accounts
for the six months ended 30 June 2024 by 30 September 2024; annual
accounts for the year ended 31 December 2024 by 30 June 2025;
interim accounts for the six months ended 30 June 2025 by 30
September 2025
|
|
EXPECTED ADMISSION DATE:
|
|
31 May 2024
|
|
NAME AND ADDRESS OF NOMINATED
ADVISER:
|
|
S.P. Angel Corporate Finance LLP,
Prince Frederick House, 35-39 Maddox Street, Mayfair, London, W1S
2PP
|
|
NAME AND ADDRESS OF
BROKER:
|
|
S.P. Angel Corporate Finance LLP,
Prince Frederick House, 35-39 Maddox Street, Mayfair, London, W1S
2PP
|
|
OTHER THAN IN THE CASE OF A
QUOTED APPLICANT, DETAILS OF WHERE (POSTAL
OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM,
WITH A STATEMENT THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE
APPLICANT AND THE ADMISSION OF ITS SECURITIES:
|
|
Copies of the document will be
available free of charge to the public during normal business hours
on any day (Saturdays, Sundays and public holidays excepted) at the
offices of S.P. Angel Corporate Finance LLP, Prince Frederick
House, 35-39 Maddox Street, Mayfair, London, W1S 2PP in accordance
with the AIM Rules. The document will also be available for
download from the Company's website at www.amurminerals.com up
to Admission and at www.crismtherapeutics.com post
Admission.
|
|
THE CORPORATE GOVERNANCE CODE THE
APPLICANT HAS DECIDED TO APPLY
|
|
The QCA Corporate Governance
Code
|
|
DATE OF NOTIFICATION:
|
|
15 May 2024
|
|
NEW/ UPDATE:
|
|
New
|